003000.KS
Bukwang Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 3,700.00
−1.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 225.3B | 200.7B | 160.1B | 125.9B | 190.9B |
| Cost of Revenue | 88.0B | 105.0B | 85.7B | 75.9B | 111.5B |
| Gross Profit | 79.3B | 95.7B | 74.3B | 50.0B | 79.4B |
| Operating Expenses | |||||
| R&D Expense | 13.8B | 25.1B | 23.4B | 34.6B | 24.3B |
| SG&A Expense | 38.0B | 24.8B | 16.8B | 22.1B | 19.8B |
| General & Admin Expense | 19.0B | 5.5B | 4.3B | 4.5B | 5.1B |
| Selling & Marketing Expense | 2.9B | 19.4B | 12.5B | 17.6B | 14.8B |
| Other Expenses | 82.3B | 31.7B | 32.5B | 30.9B | 35.6B |
| Total Operating Expenses | 124.4B | 81.6B | 72.7B | 87.5B | 79.7B |
| Cost and Expenses | 212.4B | 186.6B | 158.5B | 163.4B | 191.1B |
| Operating Income (EBIT) | 12.8B | 14.2B | 1.6B | (37.5B) | (230.6M) |
| Non-Operating | |||||
| Interest Income | 4.7B | 4.7B | 4.4B | 3.1B | 1.4B |
| Interest Expense | (1.7B) | 3.9B | 6.5B | 3.8B | 1.8B |
| Net Interest Income | 6.4B | 815.6M | (2.1B) | (727.8M) | (320.3M) |
| Other Non-Op Income/Expense | (3.9B) | (7.8B) | (4.6B) | (2.1B) | (802.2M) |
| Non-Operating Income (excl Interest) | — | — | (1.9B) | (1.7B) | — |
| EBT (Pre-Tax Income) | 9.0B | 6.4B | (3.0B) | (39.6B) | (1.0B) |
| Income Tax Expense | 778.3M | (6.0B) | 489.2M | (5.2B) | 3.2B |
| Bottom Line | |||||
| Net Income | 8.2B | 12.6B | (2.6B) | (31.3B) | (2.5B) |
| Earnings from Cont. Ops | 8.2B | 12.4B | (3.5B) | (34.4B) | (4.2B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 8.2B | 12.6B | (2.6B) | (31.3B) | (2.5B) |
| Per Share | |||||
| Basic EPS | ₩58 | ₩152 | (₩39) | (₩458) | (₩36) |
| Diluted EPS | ₩58 | ₩152 | (₩39) | (₩458) | (₩36) |
| Revenue Per Share | ₩2,243 | ₩2,034 | ₩2,339 | ₩1,841 | ₩2,789 |
| Shares | |||||
| Basic Shares Outstanding | 100.4M | 98.7M | 68.5M | 68.4M | 68.5M |
| Diluted Shares Outstanding | 100.4M | 98.7M | 68.5M | 68.5M | 68.5M |
| Profitability Metrics | |||||
| EBITDA | 16.5B | 19.7B | 7.6B | (31.5B) | 4.9B |
| D&A | 3.7B | 5.5B | 4.1B | 4.3B | 5.1B |
| EBIT | 12.8B | 14.2B | 3.5B | (35.8B) | (230.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026